Platelets and Vascular Risk: An Option for Treatment

Author(s): I. A. Jagroop, A. I. Kakafika, D. P. Mikhailidis

Journal Name: Current Pharmaceutical Design

Volume 13 , Issue 16 , 2007

Become EABM
Become Reviewer
Call for Editor


Epidemiological studies have linked platelet hyperactivity with an increased risk of vascular events. Even more convincing is the evidence from appropriately designed clinical trials showing that antiplatelet agents decrease the risk of vascular events (e.g. myocardial infarction, MI and stroke). These findings are compatible with the known thrombotic action of platelets. A considerable limitation in platelet research is the absence of a reliable, universally accepted marker of platelet activity. Therefore, it is difficult to reliably identify the ‘high risk patient’ and/or evaluate the efficacy of any administered treatment other than by calculating event rates over a period of time. This review will focus on the preventive aspects of antiplatelet intervention while also briefly considering the assessment of platelet hyperactivity and the mechanisms involved in platelet-induced thrombosis.

Keywords: Platelet, aggregation, thrombosis, aspirin, clopidogrel, myocardial infarction, stroke

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2007
Page: [1669 - 1683]
Pages: 15
DOI: 10.2174/138161207780831383
Price: $65

Article Metrics

PDF: 3